<DOC>
	<DOCNO>NCT02654002</DOCNO>
	<brief_summary>This study evaluate safety tolerability escalate single- multiple-oral dos GS-9674 , characterize single- multiple-dose pharmacokinetics ( PK ) GS-9674 . The study conduct 3 part ( Part A , Part B , Part C ) . Participants receive either GS-9674 GS-9674 placebo . Part A proceed 4 prespecified stagger cohort . Within cohort , cumulative , blind safety data evaluate dose escalation single-dose ( Period 1 ) multiple-dose ( Period 2 ) . Based available safety , pharmacokinetics , and/or pharmacodynamics ( PD ) data cohort Part A Part C ( applicable ) , total daily dos frequency dose choose cohort Part B . Parts B C consist adaptive cohort may initiate parallel . Part B cohort may initiate parallel cohort Part A total dose evaluation dose already evaluate . This study partially blind ( one blind Day -1 ) .</brief_summary>
	<brief_title>Study Healthy Volunteers Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics GS-9674 , Effect Food GS-9674 Pharmacokinetics Pharmacodynamics</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Healthy male nonpregnant , nonlactating female volunteer Body mass index ( BMI ) 19 ≤ BMI ≤ 30 kg/m^2 Normal 12lead electrocardiogram ( ECG ) one abnormality consider clinically insignificant investigator Normal renal function ( estimate glomerular filtration rate calculate use CockcroftGault equation ≥ 80 mL/min ) No significant medical history , good general health determine investigator screen evaluation perform 28 day prior schedule first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>